Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million
Deal Value:
Coherus BioSciences has agreed to sell its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4 million.
Purpose:
The sale is intended to support Coherus BioSciences' ambitions in immuno-oncology.
Product:
Udenyca is a biosimilar of pegfilgrastim, used to prevent infections in patients undergoing chemotherapy.
Buyer:
Intas Pharmaceuticals, a global pharmaceutical company, will acquire the Udenyca franchise.
Seller:
Coherus BioSciences, a biotechnology company, is divesting its Udenyca franchise to focus on other areas, particularly immuno-oncology1.